ir.neogenomics.comNeoGenomics, Inc. (NEO)

866.776.5907 Search 866.776.5907 Toggle navigation DIAGNOSTIC SERVICES New Tests Test Methodologies Cytogenetics FISH Flow Cytometry IHC & ISH Molecular Specialty Testing Hemopathology Overview NeoCOMPLETE TM Solid Tumors Overview Cancer TYPE ID ® Immuno-oncology NeoTYPE ® Cancer Profiles Overview NeoTYPE ® Cancer Specific Profiles NeoTYPE ® Broad Reach Tumor Profiles NeoLAB™ Liquid Biopsy Overview NeoLAB™ Liquid Biopsy for Hematologic Diseases NeoLAB™ Solid Tumor Monitor NeoLAB™ EGFR T790M Liquid Biopsy NCI-MATCH Pediatric Oncology Hereditary Cancer Test Spotlight Tech-Only Program Overview Virtual HemeFISH ® Getting Started With NeoGenomics PHARMA SERVICES Pharma Services Overview Ordering Logistics Blog: Pharma Services Insights Why Choose NeoGenomics Overview Global Capabilities Expertise Lab Services Overview Anatomic Pathology Cytogenetics FISH Flow Cytometry Molecular MultiOmyx™ IVD Services Healthcare Information Services Request More Information TEST MENU CLIENT SERVICES Test Ordering & Pickup Overview Forms & Kits Specimen Pickup Online Ordering Education Powering Precision: A Blog NeoUniversity™ Publications, Abstracts, and Posters On-Demand Webinars Billing Client Billing Patient Billing Third Party Billing Prior Authorization COMPANY Overview Leadership Leadership Team Medical & Scientific Team Scientific Advisory Board Careers Overview Benefits Events Investors Press Releases Newsletter Regulatory Contact Us 0 Search NeoLink ® Log In Diagnostic Services New Tests Test Methodologies Cytogenetics FISH Flow Cytometry IHC & ISH Molecular Specialty Testing Hematopathology Overview NeoCOMPLETE TM Solid Tumors Overview CancerTYPE ID ® Immuno-Oncology Cancer Profiles Overview NeoTYPE ® Cancer-Specific Profiles NeoTYPE ® Broad Reach Tumor Profiles NeoLAB™ Liquid Biopsy Overview NeoLAB™ Liquid Biopsy for Hematologic Diseases NeoLAB™ Solid Tumor Monitor NNeoLAB™ EGFR T790M Liquid Biopsy NCI-MATCH Pediatric Oncology Hereditary Cancer Test Spotlight Tech-Only Program Overview Virtual HemeFISH ® Get Started with NeoGenomics Pharma Services Overview Overview Ordering Logistics Pharma Services Insights Why Choose NeoGenomics? Overview Global Capabilities Expertise Lab Services Overview Overview Cytogenetics FISH Flow Cytometry Molecular MultiOmyx™ IVD Services Healthcare Information Services Request More Information Test Menu Client Services Overview Test Ordering and Pickup Overview Forms and Kits Specimen Pick-Up Online Ordering Education Powering Precision: A Blog NeoUniversity™ Publications, Abstracts and Posters On-Demand Webinars Billing Client Billing Patient Billing Third Party Billing Prior Authorization Company Overview Leadership Leadership Team Medical and Scientific Team Scientific Advisory Board Careers Overview Benefits Events Investors Press Releases Newsletter Regulatory and Licensing Contact Us NEOLINK® LOGIN × 2020 Third Quarter Conference Call October 27, 2020 • 8:30 AM ET Learn More Oct 27, 2020 • 7:00 AM EDT Q3 2020 Quarterly Results Quarter Ended Sep 30, 2020 View Press Release View Filing Webcast Consolidated revenue increased 20% to $125 million Clinical Services revenue increased 17% to $109 million Pharma Services revenue increased 38% to $17 million Pharma Services backlog increased 57% to $185 million NeoGenomics to Build State-of-the-Art Oncology Laboratory and Global Headquarters in Fort Myers, Florida View Release NeoGenomics Announces New $250 Million Credit Agreement View Release NeoGenomics and QIAGEN Collaborate to Offer Companion Diagnostic Test for HR+/HER2 - Advanced Breast Cancer Patients to Detect a PIK3CA Mutation View Release Investors IR Overview News / Events / Webcasts Overview Presentations Press Releases IR Calendar Email Alerts Company Info Overview Executive Leadership Contacts FAQ Financial Info Overview Balance Sheet Income Statement Cash Flow Financial Results Stock Data Overview Quote Charts Historical Data Analyst Coverage SEC Filings Overview All SEC Filings Annual Reports Quarterly Reports Section 16 Filings Governance Overview Board of Directors Board Committees Governance Documents Investor Relations Investor Relations IR Overview News / Events / Webcasts Company Information Financial Information Stock Data SEC Filings Corporate Governance Email Alerts Tear Sheet Contacts RSS News Feed Latest News Nov 13, 2020 NeoGenomics To Virtually Participate In Fireside Chat At The Stephens Annual Investment Conference 2020 Read Press Release Recent Events November 17, 2020 Stephens Annual Investment Conference 2020 Webcast Company Profile NeoGenomics, Inc. specializes in cancer genetic testing and information services. The Company provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company’s Pharma Services division serves pharmaceutical clients in clinical trials and drug development. Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories in Ft. Myers and Tampa, Florida; Aliso Viejo, Carlsbad and Fresno California; Houston, Texas; Atlanta, Georgia; Nashville, Tennessee; Rolle, Switzerland, and Singapore. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia. View Investor Presentation Latest Quarterly Results Q3 2020 Quarter Ended Sep 30, 2020 PDF HTML Release Audio Earnings Webcast PDF Management's Prepared Remarks PDF HTML 10-Q Filing ZIP XLS HTML XBRL Latest 10-K View Latest 10-K Sign up for email alerts Sign up today NeoGenomics, Inc. | View Detailed Stock Info Nasdaq: NEO Market/Symbol Price Change Volume Day Range 52 week Range Leadership View Management Team View Board of Directors IR Contact Information Investor Relations Doug Brown Chief Strategy and Corporate Development Officer T: 239.768.0600 x2539 M: 704.236.2064 doug.brown@neogenomics.com Charlie Eidson Manager of Investor Relations and Manager of Strategy and Corporate Development T: 239.768.0600 x2726 M: 952.221.8816 charlie.eidson@neogenomics.com Transfer Agent Standard Registrar & Transfer Company 12528 South 1840 East Draper, UT 84020 T: (801) 571-8844 © 2020 NeoGenomics Laboratories, Inc. Contact Us | Careers | Licensing | Terms | Privacy sfy39587stp16...